Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

• Unité de recherche: INNOSUISSE
• Numéro de projet: 104.824 IP-LS
• Titre du projet anglais: Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

Mots-clé (Anglais)

Life sciences, Medtech

Résumé des résultats (Abstract) (Anglais)

Osteoarthritis(OA) is a degenerative joint disease for which no disease-modifying drugs are available. Philochem AG and ETH Zurich will develop novel immunocytokines and evaluate delivery and screening systems to select the best candidate for the clinical development of a groundbreaking OA therapy.